ATX and IL-6 levels were shown to correlate in ACLF (73), ARDS (62) and COVID-19 (61) patients, suggesting that simultaneous inhibition of both IL-6 and ATX may be an effective therapeutic strategy for COVID-19, as previously suggested in systemic sclerosis (74). Here, IL6 is linked to systemic sclerosis.